Samsung Biologics voluntarily disclosed its '2026 ESG Report' on June 1, 2026, covering economic, social, and environmental performance from January 1 to December 31, 2025
The report complies with GRI Standards 2021, received third-party verification (Type 1 Moderate) from BSI, and references ISSB, SASB, ESRS, and other global frameworks
Key sections include governance, risk management, ethics (Governance), climate change, circular economy (Environmental), talent, human rights, safety management (Social)
Quantitative performance is published separately in an ESG Factbook (available on the company website) with three-year data (2023-2025)
[AI Summary]This is a routine ESG disclosure demonstrating Samsung Biologics' commitment to sustainability, but it does not contain any material financial events or changes in shareholder return policy. Thus, its short-term stock price impact is neutral and serves as a reference for long-term ESG risk assessment
KOSPI Filing Information
Filing: Matters Related to Sustainability Management Report, etc. (Voluntary Disclosure)